Full Text View
Tabular View
No Study Results Posted
Related Studies
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes (BEACON)
This study has been terminated.
( IDMC recommendation for safety concerns )
Study NCT01351675   Information provided by Reata Pharmaceuticals, Inc.

First Received on December 3, 2010.   Last Updated on November 1, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Renal Insufficiency, Chronic
Diabetes Mellitus, Type 2
Additional conditions recognized in this trial
Diabetes Mellitus
Kidney Diseases
Kidney Failure, Chronic
Renal Insufficiency
More general conditions related to this trial
Endocrine System Diseases
Glucose Metabolism Disorders
Metabolic Diseases
Urologic Diseases
Interventions listed in this trial
Placebo
Bardoxolone Methyl: 20 mg
Sponsors listed in this trial
Reata Pharmaceuticals, Inc.


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services